Across the United States, thousands of patients newly diagnosed with blood cancers are discovering that a doctor's prescription is only the beginning of a longer, more uncertain journey. A large-scale study from the University of Pennsylvania has traced the path these prescriptions travel — through insurer gatekeeping, bureaucratic delay, and finally the pharmacy counter — finding that the system fails most patients at least once, and many patients twice. The findings invite a deeper question about what a society owes its most vulnerable members when the medicine exists but the pathway to it d
Study: Insurance barriers, high costs delay blood cancer drug access for thousands
Patients with blood cancers experience delayed or foregone treatment due to insurance barriers and high costs, potentially affecting survival outcomes for those unable to afford medications.
Patients stopped at the pharmacy counter because they could not afford it.
Mark
So the study tracked 12,000 patients. What exactly were researchers measuring?
Mimi
They followed prescriptions from the moment a pharmacy submitted them to an insurer, through approval or rejection, and then whether patients actually filled them within 90 days. It's the full journey.
Luke
And they had claims data for all of that? Because prior authorization decisions and fill rates are usually documented, but the reasons behind rejections—whether they were clinically sound or just bureaucratic—that's harder to pin down.
Mimi
Right. The researchers explicitly said they couldn't determine if the initial rejections were appropriate. They just saw that 65 percent of Medicare prescriptions and 84 percent of commercial prescriptions were rejected initially.
Mark
That's a huge number. But then most of them got approved eventually?
Mimi
Yes. Within 90 days, Medicare approvals reached 85 percent and commercial reached 62.9 percent. So the rejections were often temporary.
Luke
Which suggests prior authorization might be creating delay without ultimately changing the outcome. But we don't know if that delay mattered clinically—whether it affected treatment timing or outcomes.
Mimi
That's the gap the study can't fill. What it does show is that even after approval, patients with higher out-of-pocket costs simply didn't fill the prescription.
Mark
How much higher are we talking?
Mimi
When Medicare patients faced costs under $15, about 85 percent filled the prescription. When costs hit $500 to $2,000, only 29 percent did.
Luke
And we're talking about blood cancer drugs here. These aren't optional medications.
Mimi
Exactly. These are life-prolonging treatments. The study doesn't track what happened to patients who didn't fill them, but the implication is clear.
Mark
So the system has two failure points—insurance approval and then cost at the pharmacy.
Mimi
Two distinct barriers, yes. And they affect different populations differently. Commercial patients had higher rejection rates initially but lower final approval rates than Medicare patients.
The Pulse
- Most blood cancer prescriptions are rejected outright at first submission — 65% for Medicare patients and a staggering 84% for those with commercial insurance — creating an immediate crisis of access at the moment patients are most vulnerable.
- Prior authorization requirements and outright coverage denials are the primary culprits, forcing patients and physicians into a bureaucratic appeals process that imposes delay even when insurers ultimately approve the same drug anyway.
- Approval alone offers no guarantee: fewer than half of commercially insured patients and just over half of Medicare patients actually filled their prescriptions within 90 days of approval.
- Out-of-pocket cost acts as a second, brutal filter — fill rates collapse from 80% when costs are minimal to below 22% when patients face bills exceeding $2,000, leaving many to simply go without.
- Researchers and advocates are now pressing for systemic reforms to prior authorization rules, coverage classifications, and cost-sharing structures to prevent insurance plan design from determining who lives and who does not.
Across the United States, thousands of patients newly diagnosed with blood cancers are discovering that a doctor's prescription is only the beginning of a longer, more uncertain journey. A large-scale study from the University of Pennsylvania has traced the path these prescriptions travel — through insurer gatekeeping, bureaucratic delay, and finally the pharmacy counter — finding that the system fails most patients at least once, and many patients twice. The findings invite a deeper question about what a society owes its most vulnerable members when the medicine exists but the pathway to it does not.
A study tracking more than 12,000 patients newly prescribed oral blood cancer medications has revealed a two-stage system of failure — one at the insurer's desk, and another at the pharmacy counter. Researchers at the University of Pennsylvania followed prescriptions for leukemias, lymphomas, and multiple myeloma through a 90-day window in 2022, mapping where and why patients lost access to drugs their doctors believed could extend their lives.
The first barrier was rejection. Nearly 65 percent of Medicare prescriptions were turned away at initial pharmacy submission; for commercially insured patients, the rate reached 84 percent. Prior authorization demands and outright coverage denials were the leading causes. Many rejections were eventually reversed — Medicare approval rates climbed to 85 percent over 90 days, commercial rates to nearly 63 percent — but the researchers noted that prior authorization imposed real delay and burden even in cases where insurers approved the same drug in the end.
Approval, however, was not the finish line. Among Medicare patients with approved prescriptions, only 54.5 percent filled them. For commercial patients, the rate was 45.5 percent. The deciding factor was cost. Medicare patients facing copayments of $15 or less filled prescriptions at a rate of nearly 85 percent. When costs rose above $500, that rate fell below 30 percent. Commercially insured patients showed an even steeper drop, with fill rates collapsing to 21.6 percent at costs exceeding $2,000.
These oral cancer therapies represent a meaningful advance — targeted treatments patients can take at home rather than endure in a hospital. But their promise depends on patients actually receiving them. Senior author Jalpa Doshi described the pharmacy counter as a second obstacle that follows the first: even patients who clear the insurer's approval process must then decide whether they can afford to pay. The study, conducted with researchers from MD Anderson, Yale, and Columbia and funded by Blood Cancer United, concludes that reforms to prior authorization rules, coverage classifications, and cost-sharing mechanisms may be necessary before access to these life-prolonging drugs is determined by medicine rather than by insurance plan design.
A nationwide study of more than 12,000 patients has documented a stark pattern: people newly prescribed oral blood cancer medications face a gauntlet of insurance obstacles and cost barriers that often prevent them from ever filling their prescriptions. Researchers at the University of Pennsylvania's Perelman School of Medicine tracked prescriptions for leukemias, lymphomas, and multiple myeloma from the moment they were submitted to pharmacies through insurer approval and into patients' hands—or not—over a 90-day window in 2022. What they found was a system that rejects most prescriptions initially, then imposes a second filter at the pharmacy counter when patients confront the actual price tag.
These oral medications represent a genuine advance in cancer treatment. Unlike older chemotherapy regimens, they are targeted therapies that patients can take at home, transforming what was once a hospital-based ordeal into something more manageable. But that promise depends entirely on patients being able to access them. Because insurers classify these drugs as pharmacy benefits rather than medical benefits, they apply the same approval machinery used for routine prescriptions—prior authorization requirements, coverage restrictions, cost-sharing formulas—to medications that can extend life.
The initial rejection rates were severe. Among Medicare patients, nearly 65 percent of prescriptions were rejected at first submission. For commercially insured patients, the rate was even worse: 84 percent. The most common culprits were prior authorization requirements—insurers demanding proof that the drug was medically necessary before they would pay—and outright coverage denials. Among commercial patients, 27.8 percent were initially rejected because prior authorization was required, and another 27.8 percent because the drug simply was not covered by their plan. Over the next 90 days, many of these rejections were reversed. Medicare approval rates climbed to 85 percent; commercial rates reached 62.9 percent. But the researchers could not determine whether those initial rejections were clinically justified or simply bureaucratic friction. What they could see was that prior authorization imposed work and delay in cases where insurers ultimately approved the same drug anyway.
Even approval, though, did not guarantee access. Among Medicare patients with approved prescriptions, only 54.5 percent actually filled them within 90 days. For commercial patients, the rate was 45.5 percent. The difference between those who filled and those who did not correlated sharply with out-of-pocket cost. When Medicare patients faced copayments of $15 or less, 84.9 percent filled their prescriptions. When costs climbed to between $15 and $175, the fill rate dropped to 76.7 percent. For costs between $175 and $500, it fell to 38 percent. And when patients faced out-of-pocket costs between $500 and $2,000, only 29.2 percent filled the prescription. Commercially insured patients showed a similar cliff: 80 percent fill rates at $15 or less, plummeting to 21.6 percent when costs exceeded $2,000.
These are not abstract numbers. They represent thousands of people with blood cancers who obtained a prescription for a drug their doctor believed would help them, cleared an insurance hurdle, and then stopped at the pharmacy counter because they could not afford it. Jalpa Doshi, the study's senior author, framed it plainly: getting an insurer to approve a cancer drug is only the first obstacle. The second one waits at the pharmacy, where patients must decide whether to pay or go without.
The study, funded by Blood Cancer United and conducted in collaboration with researchers from MD Anderson Cancer Center, Yale University, and Columbia University, raises questions about whether the insurance system is designed for these drugs at all. Medicare beneficiaries now have some new tools—an annual out-of-pocket cost cap and a prescription payment plan that allows costs to be spread over the year—but awareness and enrollment remain low. Commercially insured patients have fewer protections. The researchers suggest that changes to prior authorization rules, drug coverage policies, and cost-sharing mechanisms may be necessary to ensure that access to life-prolonging medications is not determined by insurance plan design.
Notable Quotes
Getting an insurer to approve a cancer drug is only the first hurdle. We saw a second drop-off at the pharmacy counter when patients faced high out-of-pocket costs.— Jalpa A. Doshi, senior author, University of Pennsylvania
Want the full story?
Read the original at News-Medical ↗